These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24528425)

  • 1. Acute myopericarditis following intravenous zoledronic acid for the treatment of Paget's disease.
    Watts MR; Ellims AH; Eccleston DS
    Med J Aust; 2014 Feb; 200(3):150. PubMed ID: 24528425
    [No Abstract]   [Full Text] [Related]  

  • 2. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
    Keating GM; Scott LJ
    Drugs; 2007; 67(5):793-804. PubMed ID: 17385948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paget's disease and bisphosphonate-associated osteonecrosis of the jaws.
    Gueiros LA; Lopes MA; Leão JC
    J Oral Maxillofac Surg; 2008 Jun; 66(6):1319. PubMed ID: 18486809
    [No Abstract]   [Full Text] [Related]  

  • 4. Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study.
    Buckler H; Fraser W; Hosking D; Ryan W; Maricic MJ; Singer F; Davie M; Fogelman I; Birbara CA; Moses AM; Lyles K; Selby P; Richardson P; Seaman J; Zelenakas K; Siris E
    Bone; 1999 May; 24(5 Suppl):81S-85S. PubMed ID: 10321935
    [No Abstract]   [Full Text] [Related]  

  • 5. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent effect of zoledronic acid in Paget's disease.
    Tziomalos K; Florentin M; Krikis N; Perifanis V; Karagiannis A; Harsoulis F
    Clin Exp Rheumatol; 2007; 25(3):464-6. PubMed ID: 17631747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone.
    Gennari L; Merlotti D; Mossetti G; Rendina D; De Paola V; Martini G; Nuti R
    Mini Rev Med Chem; 2009 Aug; 9(9):1052-63. PubMed ID: 19689402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid for Paget's disease of bone.
    Maricic M
    Drugs Today (Barc); 2007 Dec; 43(12):879-85. PubMed ID: 18174973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intravenous bisphosphonates for bone Paget's disease: higher risk of adverse events].
    Grados D; Martínez-Morillo M; Holgado S; Erra A
    Med Clin (Barc); 2014 May; 142(10):469-70. PubMed ID: 24120108
    [No Abstract]   [Full Text] [Related]  

  • 10. Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
    Krane SM
    Nat Clin Pract Rheumatol; 2006 Apr; 2(4):186-7. PubMed ID: 16932682
    [No Abstract]   [Full Text] [Related]  

  • 11. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient.
    Mishra A
    J Postgrad Med; 2008; 54(3):237. PubMed ID: 18626181
    [No Abstract]   [Full Text] [Related]  

  • 12. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.
    Reid IR; Lyles K; Su G; Brown JP; Walsh JP; del Pino-Montes J; Miller PD; Fraser WD; Cafoncelli S; Bucci-Rechtweg C; Hosking DJ
    J Bone Miner Res; 2011 Sep; 26(9):2261-70. PubMed ID: 21638319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory complications associated with IV zoledronic acid infusion in the treatment of postmenopausal osteoporosis.
    Taggart H; Cheng J; Archbold P
    Osteoporos Int; 2010 Sep; 21(9):1621-2. PubMed ID: 19813042
    [No Abstract]   [Full Text] [Related]  

  • 14. Paget's disease of bone and osteonecrosis.
    Seehra J; Sloan P; Oliver RJ
    Dent Update; 2009 Apr; 36(3):166-8, 171-2. PubMed ID: 19480105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paget disease manifesting with compressive sixth-nerve palsy that resolved with intravenous zoledronic acid therapy.
    Pane A
    Arch Ophthalmol; 2007 Oct; 125(10):1440-1. PubMed ID: 17923566
    [No Abstract]   [Full Text] [Related]  

  • 16. [Zoledronic acid for preventing fractures. HORIZON trial (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)].
    Ringe JD; Nitschmann S
    Internist (Berl); 2008 Apr; 49(4):502-4. PubMed ID: 18305914
    [No Abstract]   [Full Text] [Related]  

  • 17. [Zoledronic acid efficacy in Paget's disease of bone: a three-year experience].
    Conesa Mateos A; Rotés Sala D; Almirall Bernabé M; Carbonell Abelló J
    Med Clin (Barc); 2006 Oct; 127(16):635-6. PubMed ID: 17145033
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of zoledronic acid for Paget's disease of bone.
    Maricic M
    Curr Osteoporos Rep; 2006 Mar; 4(1):40-4. PubMed ID: 16527007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bilateral Ocular Pain and Hyperemia in a Patient With Paget Disease of the Bone.
    Haider AS; Burbidge AM; Dunlop A
    JAMA Ophthalmol; 2017 Jun; 135(6):665-666. PubMed ID: 28358955
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
    N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.